On May 5, 2017 the Canadian drug regulatory agency issued this Dear Healthcare Professional Letter: “ARANESP – Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis”. From this recent Health Canada Aranesp alert we get this updated drug safety information: In some patients, ARANESP has been associated with … [Read more...]